CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...
A CSL manufacturing expansion, tipped to come online by 2031, will create at least 300 new direct jobs at its facility in Kankakee, Illinois, adding to the site’s current workforce of more than 1,200.
The plasma-derived therapies maker will expand its U.S. presence over five years, CSL said in a press release. (CSL Behring) Amid uncertainty for its vaccine division, CSL is growing the footprint of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results